- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06831526
Quimiorradioterapia neoadjuvante com ou sem azeliragon concomitante em pacientes com glioblastoma recém -diagnosticado
Uma Janela de OpportUnidade Primeira Fase I randomizou estudo de quimiorradioterapia neoadjuvante com ou sem azeliragon concomitante em pacientes com glioblastoma recém-diagnosticado
Preclinical data have demonstrated the combination of azeliragon, a RAGE inhibitor, with radiation therapy (RT) can effectively reduce immune-suppressive myeloid cells and restore T-cell activation to improve tumor control in murine glioma models. Ongoing clinical studies of azeliragon with RT alone and RT plus temozolomide (TMZ) to treat patients with newly diagnosed glioblastoma (GBM) have demonstrated safety and tolerability. The purpose of this window-of-opportunity study is to validate that the combination of azeliragon with RT and TMZ would modulate immune-suppressive myeloid and T cells in the tumor microenvironment in patients with GBM.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase inicial 1
Contactos e Locais
Locais de estudo
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Histologically proven diagnosis of IDH-wildtype GBM (WHO grade 4) according to the 2021 WHO classification (including subtypes such as gliosarcoma).
-
Radiographic evidence of residual tumor after initial surgery or biopsy.
-
Patient is amenable for future surgery (either surgical resection or laser interstitial thermal therapy (LITT)) to sample the residual tumor after completion of chemoradiotherapy.
-
At least 18 years of age.
-
Eligible for and planning to receive standard fractionated RT of 60 Gy with concurrent TMZ.
-
Recovered from the effects of surgery, postoperative infection, and other complications sufficiently for initiation of chemoradiotherapy, in the opinion of the treating physician.
-
Karnofsky performance status ≥ 60.
-
Adequate organ and bone marrow function as defined below:
- Absolute neutrophil count (ANC) ≥ 1.5 K/cumm;
- Platelets ≥ 100 K/cumm;
- Hemoglobin > 9.0 g/dL (Note: the use of transfusion or other intervention to achieve Hgb >9.0 g/dL is acceptable);
- Total bilirubin ≤ 1.5 ULN
- AST (SGOT) and ALT (SGPT) ≤ 3 x ULN
- Creatinine ≤ 1.5 ULN or creatinine clearance ≥ 60 mL/min
- If there is history of human immunodeficiency virus (HIV) infection, patients must be on effective antiretroviral therapy, and HIV viral load must be undetectable within 6 months of study enrollment.
- If there is history of chronic hepatitis B virus (HBV) infection, patients must have either been treated or are on suppressive therapy (as indicated), and HBV viral load must be undetectable.
- If there is history of hepatitis C virus (HCV) infection, patients must have been treated, and HCV viral load must be undetectable.
-
Females of childbearing potential (defined as a female who is non-menopausal or surgically sterilized) and sexually active heterosexual males must be willing to use an acceptable method of birth control (i.e., hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) during the trial and for 6 months after the last administration of azeliragon. Should a female trial participant or female partner of a male trial participants become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
-
Able to understand and willingness to sign an IRB-approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.
Exclusion Criteria:
- Prior cranial RT or RT to the head and neck where potential field overlap may exist.
- Leptomeningeal or metastatic involvement.
- Known IDH mutation. IDH status could be determined by either immunohistochemistry or sequencing as evaluated per routine clinical care.
- Patients receiving CYP 2C8 inhibitors within 2 weeks or 5 half-lives prior to study entry.
- Patients with a gastrointestinal condition that could interfere with swallowing or absorption.
- Patients with concurrent participation in another interventional clinical trial or use of another investigational agent within 30 days prior to study entry. Patients who are participating in non-interventional clinical trials (e.g., QOL, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation.
- Medical contraindication to MRI (e.g., unsafe foreign metallic implants, incompatible pacemaker, inability to lie still for long periods, severe to end-stage kidney disease or on hemodialysis).
- Pregnant or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of the first dose of RT (Arm 1) or azeliragon (Arm 2).
- Patients with psychiatric illness/social situations, including alcohol or drug abuse that in the investigator's opinion will prevent administration or completion of protocol therapy.
- Non-English speaking, as the cognitive assessments will only be available in English
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Arm 1: Neoadjuvant RT and Temozolomide (TMZ) + Surgery or LITT + Adjuvant TMZ & Azeliragon
Radiation therapy (RT) will consist of fractionated RT to 60 Gy in 30 daily fractions administered per standard of care RTOG approach. Concurrent TMZ during RT will be self-administered by mouth (PO) as per standard of care. 1 month after completion of RT, patient will proceed with planned surgery of either resection or LITT. Patients will then receive adjuvant TMZ and azeliragon for up to 6 months. Patient should start with the loading dose 30 mg BID for 6 days before the start of adjuvant TMZ. After 6 days, azeliragon 20 mg once daily should be continued in combination with TMZ. |
Provided by Cantex Pharmaceuticals Standard of care.
Outros nomes:
Standard of care. Standard of care surgical resection or laser interstitial thermal therapy (LITT). |
|
Experimental: Arm 2: Neoadjuvant RT, Temozolomide (TMZ) & Azeliragon + Surgery or LITT + Adjuvant TMZ & Azeliragon
RT will consist of fractionated RT to 60 Gy in 30 daily fractions administered per standard of care RTOG approach. Concurrent TMZ during RT will be self-administered by mouth (PO) as per standard of care. Patients will receive azeliragon as well. Azeliragon is self-administered PO. Azeliragon dosing will consist of 6 days of a loading dose of 30 mg twice per day starting on day -6, followed by 20 mg daily starting on the Day 1. Concurrent RT and TMZ start on Day 1. Azeliragon should continue until the day before planned surgical procedure. 1 month after completion of RT, patient will proceed with planned surgery of either resection or LITT. Patients will then receive adjuvant TMZ and azeliragon for up to 6 months. Patient should start with the loading dose 30 mg BID for 6 days before the start of adjuvant TMZ. After 6 days, azeliragon 20 mg once daily should be continued in combination with TMZ. |
Provided by Cantex Pharmaceuticals Standard of care.
Outros nomes:
Standard of care. Standard of care surgical resection or laser interstitial thermal therapy (LITT). |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Porcentagem de células mielóides imune-supressoras no tecido tumoral
Prazo: No momento da cirurgia ou Litt (estimado no dia 60)
|
No momento da cirurgia ou Litt (estimado no dia 60)
|
|
Porcentagem de células T imunes-supressoras no tecido tumoral
Prazo: No momento da cirurgia ou Litt (estimado no dia 60)
|
No momento da cirurgia ou Litt (estimado no dia 60)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sobrevivência livre de progressão (PFS)
Prazo: Até 12 meses após a conclusão do tratamento do estudo (estimado em 21 meses)
|
Até 12 meses após a conclusão do tratamento do estudo (estimado em 21 meses)
|
|
|
Sobrevivência geral (SO)
Prazo: Até 12 meses após a conclusão do tratamento do estudo (estimado em 21 meses)
|
Até 12 meses após a conclusão do tratamento do estudo (estimado em 21 meses)
|
|
|
Número de participantes com eventos adversos
Prazo: Desde o dia 1 (braço 1) ou dia -6 (braço 2) a 30 dias após a última dose de azeliragon (estimado em 10 meses)
|
Desde o dia 1 (braço 1) ou dia -6 (braço 2) a 30 dias após a última dose de azeliragon (estimado em 10 meses)
|
|
|
Number of participants with intolerable toxicities
Prazo: From first dose of azeliragon until 30 days after the last dose (estimated to be 6-9 months)
|
The protocol lists the specific toxicities that are considered intolerable. |
From first dose of azeliragon until 30 days after the last dose (estimated to be 6-9 months)
|
|
Feasibility of the regimen as measured by the number of participants who proceed with post-chemoradiotherapy surgery or LITT
Prazo: Through surgery or LITT (estimated to be 60 days)
|
Feasibility is defined as at least 50% of patients in each arm who are able to proceed with post-chemoradiotherapy surgery or LITT. |
Through surgery or LITT (estimated to be 60 days)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jiayi Huang, M.D., Washington University School of Medicine
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Neoplasias
- Neoplasias por Tipo Histológico
- Neoplasias Glandulares e Epiteliais
- Astrocitoma
- Glioma
- Neoplasias Neuroepiteliais
- Tumores Neuroectodérmicos
- Neoplasias, Células Germinativas e Embrionárias
- Neoplasias, Tecido Nervoso
- Glioblastoma
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Terapêutica
- Azoles
- Dacarbazina
- Triazenos
- Imidazoles
- Temozolomida
- Radioterapia
- Procedimentos cirúrgicos, operatórios
- Azeliragon
Outros números de identificação do estudo
- 202504190
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .